Further pharmacological characterization of 5‐HT2Creceptor agonist‐induced inhibition of 5‐HT neuronal activity in the dorsal raphe nucleusin vivo
Authors:
Open Access
- 28 October 2009
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (6) , 1477-1485
Abstract
Background and purpose: Recent experiments using non‐selective 5‐hydroxytryptamine (5‐HT)2Creceptor agonists including WAY 161503 suggested that midbrain 5‐HT neurones are under the inhibitory control of 5‐HT2Creceptors, acting via neighbouring gamma‐aminobutyric acid (GABA) neurones. The present study extended this pharmacological characterization by comparing the actions of WAY 161503 with the 5‐HT2Creceptor agonists, Ro 60‐0275 and 1‐(3‐chlorophenyl) piperazine (mCPP), as well as the non‐selective 5‐HT agonist lysergic acid diethylamide (LSD) and the 5‐HT releasing agent 3,4‐methylenedioxymethamphetamine (MDMA).Experimental approach: 5‐HT neuronal activity was measured in the dorsal raphe nucleus (DRN) using extracellular recordings in anaesthetized rats. The activity of DRN GABA neurones was assessed using double‐label immunohistochemical measurements of Fos and glutamate decarboxylase (GAD).Key results: Ro 60‐0175, like WAY 161503, inhibited 5‐HT neurone firing, and the 5‐HT2Cantagonist SB 242084 reversed this effect. mCPP also inhibited 5‐HT neurone firing (∼60% neurones) in a SB 242084‐reversible manner. LSD inhibited 5‐HT neurone firing; however, this effect was not altered by either SB 242084 or the 5‐HT2A/Creceptor antagonist ritanserin but was reversed by the 5‐HT1Areceptor antagonist WAY 100635. Similarly, MDMA inhibited 5‐HT neurone firing in a manner reversible by WAY 100635, but not SB 242084 or ritanserin. Finally, both Ro 60‐0275 and mCPP, like WAY 161503, increased Fos expression in GAD‐positive DRN neurones.Conclusions and implications: These data strengthen the hypothesis that midbrain 5‐HT neurones are under the inhibitory control of 5‐HT2Creceptors, and suggest that the 5‐HT2Cagonists Ro 60‐0175, mCPP and WAY 161503, but not LSD or MDMA, are useful probes of the mechanism(s) involved.Keywords
This publication has 30 references indexed in Scilit:
- Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neuronsPharmacology Biochemistry and Behavior, 2008
- Guide to Receptors and Channels (GRAC), 3rd editionBritish Journal of Pharmacology, 2008
- In vivo evidence that 5‐HT2C receptors inhibit 5‐HT neuronal activity via a GABAergic mechanismBritish Journal of Pharmacology, 2006
- A role for midbrain raphe ?? aminobutyric acid neurons in 5-hydroxytryptamine feedback controlNeuroReport, 2005
- Expression of serotonin 5-HT2C receptors in GABAergic cells of the anterior raphe nucleiJournal of Chemical Neuroanatomy, 2005
- Inactivation of 5-HT2C Receptors Potentiates Consequences of Serotonin Reuptake BlockadeNeuropsychopharmacology, 2004
- Evidence that central 5‐HT2A and 5‐HT2B/C receptors regulate 5‐HT cell firing in the dorsal raphe nucleus of the anaesthetised ratBritish Journal of Pharmacology, 2003
- Agonist high and low affinity state ratios predict drug intrinsic activity and a revised Ternary complex mechanism at serotonin 5-HT2A and 5-HT2C receptorsSynapse, 1999
- Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on 5-HT cell firing and release: Comparison between dorsal and median raphe 5-HT systemsNeuropharmacology, 1997
- Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonistsSynapse, 1987